Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 6.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 121,030 shares of the company's stock after acquiring an additional 7,342 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in Novo Nordisk A/S were worth $8,404,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of NVO. M. Kulyk & Associates LLC raised its holdings in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock valued at $274,000 after purchasing an additional 119 shares during the period. Exencial Wealth Advisors LLC increased its position in Novo Nordisk A/S by 0.5% in the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock valued at $1,987,000 after buying an additional 124 shares in the last quarter. Dorsey & Whitney Trust CO LLC raised its stake in Novo Nordisk A/S by 0.4% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 31,494 shares of the company's stock worth $2,709,000 after buying an additional 136 shares during the period. BIP Wealth LLC boosted its holdings in Novo Nordisk A/S by 3.9% in the fourth quarter. BIP Wealth LLC now owns 3,642 shares of the company's stock worth $313,000 after acquiring an additional 138 shares in the last quarter. Finally, Xponance Inc. grew its stake in Novo Nordisk A/S by 4.9% in the fourth quarter. Xponance Inc. now owns 3,156 shares of the company's stock valued at $271,000 after acquiring an additional 146 shares during the period. 11.54% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on NVO. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Stifel Nicolaus downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Finally, BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Hold" and a consensus target price of $112.00.
Read Our Latest Stock Analysis on Novo Nordisk A/S
Novo Nordisk A/S Stock Performance
Shares of Novo Nordisk A/S stock opened at $67.78 on Friday. The business's fifty day simple moving average is $68.90 and its 200 day simple moving average is $77.56. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $145.99. The firm has a market capitalization of $302.64 billion, a P/E ratio of 20.05, a price-to-earnings-growth ratio of 1.20 and a beta of 0.66.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.
About Novo Nordisk A/S
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Recommended Stories
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
